214 related articles for article (PubMed ID: 34841698)
1. HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress.
Shi J; Xiong Z; Wang K; Yuan C; Huang Y; Xiao W; Meng X; Chen Z; Lv Q; Miao D; Liang H; Xu T; Xie K; Yang H; Zhang X
Clin Transl Med; 2021 Nov; 11(11):e592. PubMed ID: 34841698
[TBL] [Abstract][Full Text] [Related]
2. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
[TBL] [Abstract][Full Text] [Related]
3. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
[TBL] [Abstract][Full Text] [Related]
4. HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.
Xiao H; Qu Y; Li H; Zhang Y; Fei M; Liang C; Yang H; Zhang X
J Exp Clin Cancer Res; 2024 Jan; 43(1):29. PubMed ID: 38263248
[TBL] [Abstract][Full Text] [Related]
5. USP37 promotes deubiquitination of HIF2α in kidney cancer.
Hong K; Hu L; Liu X; Simon JM; Ptacek TS; Zheng X; Liao C; Baldwin AS; Zhang Q
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13023-13032. PubMed ID: 32461361
[TBL] [Abstract][Full Text] [Related]
6. TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy.
Huang Y; Xiong Z; Wang J; Gao Y; Cao Q; Wang D; Shi J; Chen Z; Yang X
J Transl Med; 2024 Feb; 22(1):212. PubMed ID: 38419050
[TBL] [Abstract][Full Text] [Related]
7. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
8. NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Lin Y; Zhang F; Jin Y; Zhong Q; Tan W; Liu J; Wu Z
Appl Bionics Biomech; 2022; 2022():3669296. PubMed ID: 36606241
[TBL] [Abstract][Full Text] [Related]
9. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
10. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis.
Liu XD; Yao J; Tripathi DN; Ding Z; Xu Y; Sun M; Zhang J; Bai S; German P; Hoang A; Zhou L; Jonasch D; Zhang X; Conti CJ; Efstathiou E; Tannir NM; Eissa NT; Mills GB; Walker CL; Jonasch E
Oncogene; 2015 May; 34(19):2450-60. PubMed ID: 24998849
[TBL] [Abstract][Full Text] [Related]
11. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
Gstalder C; Ader I; Cuvillier O
Mol Cancer Ther; 2016 Oct; 15(10):2465-2474. PubMed ID: 27507852
[TBL] [Abstract][Full Text] [Related]
12. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
13. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S
Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405
[No Abstract] [Full Text] [Related]
14. Aberrant activation of m6A demethylase FTO renders HIF2α
Zhang C; Chen L; Lou W; Su J; Huang J; Liu A; Xu Y; He H; Gao Y; Xu D; Li Q
Sci Transl Med; 2021 Sep; 13(613):eabf6045. PubMed ID: 34586831
[TBL] [Abstract][Full Text] [Related]
15. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
16. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
17. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
18. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma.
Zhou J; Wu K; Gao D; Zhu G; Wu D; Wang X; Chen Y; Du Y; Song W; Ma Z; Authement C; Saha D; Hsieh JT; He D
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):942-51. PubMed ID: 25585786
[TBL] [Abstract][Full Text] [Related]
20. Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis.
Mur P; Jemth AS; Bevc L; Amaral N; Navarro M; Valdés-Mas R; Pons T; Aiza G; Urioste M; Valencia A; Lázaro C; Moreno V; Puente XS; Stenmark P; Warpman-Berglund U; Capellá G; Helleday T; Valle L
Hum Mutat; 2018 Sep; 39(9):1214-1225. PubMed ID: 29900613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
